Paxlovid is an antiviral pill that blocks the virus responsible for COVID-19 from copying itself inside your cells. In a CDC study of nearly 700,000 adults diagnosed with COVID, those prescribed Paxlovid within five days of diagnosis had a 51% lower hospitalization rate over the following month compared to those who weren’t prescribed the drug. It works best for people at higher risk of severe illness, and it needs to be started early to be effective.
How Paxlovid Stops the Virus
Paxlovid is actually two drugs packaged together. The first, nirmatrelvir, targets a specific enzyme the virus needs to assemble new copies of itself. Without that enzyme functioning properly, the virus produces broken, non-functional copies and can’t spread through your body as quickly. This gives your immune system time to catch up and clear the infection.
The second drug, ritonavir, doesn’t fight the virus directly. Instead, it slows your liver from breaking down nirmatrelvir too quickly. Without ritonavir, nirmatrelvir would be metabolized and cleared from your bloodstream before it could do its job effectively. Ritonavir keeps nirmatrelvir at high enough levels, for long enough, to suppress viral replication throughout the five-day course of treatment.
Who Qualifies for a Prescription
Paxlovid is approved for adults 18 and older, as well as adolescents over 12 who weigh at least 88 pounds (40 kg). The key requirement is that you have one or more risk factors for progressing to severe COVID. Your prescriber makes that determination based on your medical history, but the CDC maintains a list of qualifying conditions that includes obesity, diabetes, heart disease, chronic lung conditions, immunocompromising conditions, and being 65 or older, among others.
If you’re young, healthy, and at low risk for severe illness, Paxlovid is generally not prescribed. The clinical benefit is clearest in people who are most likely to end up hospitalized without treatment.
The Treatment Window Matters
You must start Paxlovid within five days of your first symptoms. The sooner you begin, the better it works. This means getting tested and reaching a prescriber quickly if you’re in a high-risk group. Waiting until day six or later falls outside the window where the drug has demonstrated benefit, and a prescription at that point is unlikely to help.
The full course is five days, taken twice daily. If you have moderate or severe kidney impairment, your prescriber will reduce the dose, and you may need to discard extra tablets from the packaging since the standard daily dose pack contains more pills than you’ll need.
How Well It Works
The clearest evidence comes from real-world data collected after Paxlovid became widely available. A CDC analysis covering April through September 2022, which included both vaccinated and previously infected individuals, found that Paxlovid cut the 30-day hospitalization rate by 51%. Death rates were also lower: 0.01% among those who received Paxlovid compared to 0.04% among those who did not.
These numbers reflect a population where most people already had some immune protection from vaccines or prior infection. Even with that baseline protection, Paxlovid provided a meaningful additional reduction in severe outcomes for high-risk patients.
Common Side Effects
The most talked-about side effect is a bitter or metallic taste that some people call “Paxlovid mouth.” In clinical trials, about 6% of people taking Paxlovid reported this altered taste. The culprit is ritonavir, which caused taste changes in 16% of subjects when studied on its own. The taste is harmless and typically disappears shortly after you finish the five-day course.
Other reported side effects include diarrhea and muscle aches, but most people tolerate the drug without significant problems.
Drug Interactions to Know About
Because ritonavir affects how your liver processes many medications, Paxlovid interacts with a long list of common drugs. Among the most widely prescribed medications, the most dangerous interactions involve the blood thinner rivaroxaban (which can cause increased bleeding) and salmeterol, a long-acting inhaler ingredient (which can cause heart-related side effects). Both are considered incompatible with Paxlovid.
Several other medications require temporary adjustments during your five-day course:
- Statins (cholesterol-lowering drugs) should be paused during treatment and for five days afterward to avoid toxicity.
- Certain blood thinners like apixaban may need their dose cut in half during and shortly after treatment.
- Blood pressure medications in the calcium-channel blocker family can cause blood pressure to drop lower than usual, so your prescriber may reduce the dose if you feel lightheaded.
- Hormonal birth control containing ethinyl estradiol may become less effective. A backup method of contraception is recommended until your next full menstrual cycle after finishing Paxlovid.
This is why your prescriber needs a complete list of your current medications before writing a Paxlovid prescription. In some cases, the interactions make Paxlovid too risky, and an alternative COVID treatment is a better option.
COVID Rebound After Treatment
Some people feel better during or right after their Paxlovid course, test negative, and then develop symptoms again a few days later. This is known as COVID rebound. About 1 in 5 people who take Paxlovid experience it, though many of those cases are asymptomatic, meaning a test turns positive again without noticeable illness returning.
The leading explanation is that Paxlovid suppresses the virus so effectively during those five days that the immune system doesn’t fully finish the job. Once the drug clears your system, small amounts of remaining virus can briefly flare up. Rebound episodes are generally mild and resolve on their own. They do not mean the drug failed or that you need a second course.
Does Paxlovid Prevent Long COVID?
Early observational studies raised hopes that Paxlovid might reduce the risk of long COVID, but larger, more rigorous analyses have been disappointing. A study using data from nearly 446,000 patients found essentially no difference in long COVID rates between treated and untreated groups: 4.53% versus 4.60%.
A separate CDC-backed study found modest effects that varied by age. Adults 65 and older who took Paxlovid had a 12% lower risk of developing at least one long COVID symptom. For younger adults aged 18 to 49, the reduction was smaller at 7%. No meaningful effect was found in adolescents. In practical terms, the older-adult benefit translated to needing to treat 233 people to prevent a single case of long COVID. So while Paxlovid is highly effective at preventing hospitalization and death, it should not be considered a reliable safeguard against lingering symptoms.